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OBJECTIVEdTo examine whether diabetes genetic risk testing and counseling can improve
diabetes prevention behaviors.
RESEARCH DESIGN AND METHODSdWe conducted a randomized trial of diabetes
genetic risk counseling among overweight patients at increased phenotypic risk for type 2 di-
abetes.Participantswererandomlyallocatedtogenetictestingversusnotesting.Geneticriskwas
calculated by summing 36 single nucleotide polymorphisms associated with type 2 diabetes.
Participants in the top and bottom score quartiles received individual genetic counseling before
being enrolled with untested control participants in a 12-week, validated, diabetes prevention
program. Middle-risk quartile participants were not studied further. We examined the effect of
thisgeneticcounselinginterventiononpatientself-reportedattitudes,programattendance,and
weight loss, separately comparing higher-risk and lower-risk result recipients with control
participants.
RESULTSdThe108participantsenrolledinthediabetespreventionprogramincluded42par-
ticipantsathigherdiabetesgeneticrisk,32atlowerdiabetesgeneticrisk,and34untestedcontrol
subjects.Meanagewas57.9610.6years,61%weremen,andaverageBMIwas34.8kg/m
2,with
nodifferencesamongrandomizationgroups.Participantsattended6.864.3groupsessionsand
lost 8.5 6 10.1 pounds, with 33 of 108 (30.6%) losing $5% body weight. There were few
statistically signiﬁcant differences in self-reported motivation, program attendance, or mean
weight loss when higher-risk recipients and lower-risk recipients were compared with control
subjects (P . 0.05 for all but one comparison).
CONCLUSIONSdDiabetesgeneticriskcounselingwithcurrentlyavailablevariantsdoesnot
signiﬁcantly alter self-reported motivation or prevention program adherence for overweight
individuals at risk for diabetes.
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N
early 80 million Americans are cur-
rently at increased risk for diabetes,
with worldwide diabetes preva-
lence projected to reach 440 million by
2030 (1,2). Robust clinical trial evidence
has demonstrated that lifestyle changes
leading to increased exercise and weight
loss can substantially reduce the risk for
diabetes (3–5). Despite the relative cost-
effectiveness of nonpharmacologic ap-
proaches to diabetes prevention (6,7),
efforts to translate the intensive behavioral
change interventions of clinical trials into
thecommunitysettinghavehadonlymod-
est success (8–11).
New approaches to conveying per-
sonalrisk,suchasindividualizeddiabetes
genetic risk testing, may enable more
effective diabetes prevention (12). One
promise of genome-based “personalized
medicine” has been the potential to moti-
vate individuals to make lifestyle changes
that ameliorate their disease risk (13,14).
Type 2 diabetes is an ideal clinical para-
digmfortestingthisassumptiongiventhe
high prevalence of an easily identiﬁed pre-
disease phenotype, the strong evidence
linking behavior change to risk reduction,
suboptimal translation of proven behav-
ioral change interventions into clinical
practice, and recent rapid progress in dia-
betes genetic epidemiology.
Patients and providers have both in-
dicated that learning about higher genetic
risk results would likely motivate individ-
uals to change their behavior to prevent
diabetes (15,16). This prediction has not
yet been convincingly demonstrated in
controlled trials (17). In addition, genetic
testing that reveals a decreased genetic risk
could provide false reassurance to individ-
uals with a high phenotypic risk (18). This
concern has also not yet been rigorously
examined. Therefore, we conducted a ran-
domized, controlled trial to test the hy-
pothesis that diabetes genetic risk testing
and counseling can motivate the behavior
changes necessary to prevent diabetes.
Given the potential for false reassurance
withlower-riskresults,weseparatelyinves-
tigated the effect of disclosing increased or
decreased diabetes genetic risk compared
with untested control participants.
RESEARCH DESIGN AND
METHODS
Study design
The Genetic Counseling/Lifestyle Change
for Diabetes Prevention (GC/LC) Study
was a prospective, three-arm parallel
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ORIGINAL ARTICLEgroup,randomized,controlledclinicaltrial
conducted among individuals at increased
phenotypic risk for type 2 diabetes that
testedtwohypotheses:1)receivingahigher
diabetes genetic risk result would improve
motivationand participation in a 12-session
weekly diabetes prevention program
compared with untested control subjects;
and 2) receiving a lower diabetes genetic
risk result would decrease motivation and
participationcompared with untestedcon-
trol subjects. This study was investigator-
initiated, funded by the National Institute
of Diabetes and Digestive and Kidney Dis-
eases, and conducted at Massachusetts
General Hospital in Boston.
Details of the study design have been
published previously (19). Brieﬂy, eligi-
ble individuals were randomly allocated
using random numbers in concealed
envelopes in a four-to-one ratio to diabe-
tes genetic risk testing versus no testing.
Investigators implemented the random
allocation, enrollment, and assignment.
Participants with top and bottom quartile
ofdiabetesgeneticriskwereenrolledwith
untested control subjects into a 12-week
group-based Lifestyle Balance diabetes
prevention program modeled after the
Diabetes Prevention Program protocol
and previously validated in patients with
metabolic syndrome (9). Participants de-
termined to have average diabetes genetic
risk received their results but were not
studied further. This study was approved
by the Partners Human Research Com-
mittee Institutional Review Board. All
participants provided written informed
consent before enrollment.
Study participants
Participants were recruited from primary
care practices within our institution, with
the permission of their primary care physi-
cians, between January 2010 and March
2011.Patientswereeligibletoparticipatein
the study if they were aged 21 years or
older, overweight (deﬁned as BMI $29.1
kg/m
2 in men, $27.2 kg/m
2 in women),
met one other criterion for metabolic syn-
drome without an existing diagnosis of
type 2 diabetes (20), and were physically
ableandwillingtoparticipateina12-week
groupsessionprogramdesignedtoachieve
weight loss through dietary change and in-
creased physical activity.
Bloodsamplesforindividualsrandom-
ized to genetic testing were drawn for
diabetes genetic risk assessment and
genotypedattheBroadInstitute(Cambridge,
MA) using the Sequenom MassARRAY
iPLEXGold platform (Sequenom, Inc.,
S a nD i e g o ,C A ) .As u m m a r yg e n e t i cr i s k
scorewascalculatedfrom36successfully
genotyped risk alleles previously associ-
ated with type 2 diabetes (21).
Calculation of relative and absolute
diabetes genetic risk
Individualized genetic risk assessment
wasperformedbymultiplyingtherelative
genetic risk, as determined using diabetes
incidence data from the Framingham
Offspring Study (FOS) (22), by the abso-
lute phenotypic risk of the study popula-
tion. In FOS, 17.9% patients in the top
quartile of genetic risk score distribution
(.38) developed diabetes (46% relative
increase compared with middle two aver-
age quartiles), whereas 9.9% in the bot-
tom quartile (scores ,34) developed
diabetes(18%relativedecreasecompared
with“average”risk).Weestimatedthe ab-
solute diabetes incidence for participants
meeting our study eligibility criteria as
;11% over 3 yearsusing previously pub-
lished data from within our hospital net-
work (23). Multiplying relative genetic
risk by this absolute phenotypic-based risk
resulted in posttest absolute 3-year risk
estimates of 17% (higher genetic risk re-
cipients), 11% (untested control subjects),
and9%(lowergeneticriskrecipients)for
type 2 diabetes.
Intervention implementation
Participants with results showing higher
and lower diabetes genetic risk each
received a 15-min structured, individual
genetic counseling session conducted
by a certiﬁed genetic counselor. Details
of the session have published previously
(24). Each participant received a detailed
diabetes genetic risk report listing results
for each successfully tested single nucleo-
tide polymorphisms and the individual’s
overall diabetes genetic risk category
(Supplementary Data). The one-on-one
genetic counseling sessions explained
the genetic test results, discussed the rel-
ative contributions of genetic versus life-
style factors to the development of
diabetes, and placed the recipient’sg e -
netic risk results within the context of
his or her overall risk for diabetes. A pri-
marygoalofthecounselingsessionwasto
use the genetic test result as an opportu-
nity to encourage overall diabetes risk re-
duction through behavioral changes.
Counseled intervention participants
and untested control subjects partici-
pated in a 12-week diabetes prevention
program conducted by an experienced
dietitian from our institution’sD i a b e t e s
Center who was masked to the genetic
results. The diabetes prevention groups
combined intervention and control par-
ticipantsto eliminateany group-based in-
terventioneffects.Participantswereasked
to refrain from discussing their genetic
testing status and results. Masking was
well preserved, with the correct predic-
tion of participant testing status by the
dietitian after completion of the 12-week
program no better than chance (33.2%).
Outcome measures
We posited a causal pathway for diabetes
prevention by which changes in patient
motivation would lead to changes in the
health-relatedbehaviorsthatinturnwould
induce the physiologic changes necessary
to prevent diabetes. To capture changes in
motivation, we assessed self-reported con-
ﬁdence and motivation to make diabetes-
related lifestyle changes (exercise, weight
loss, and adoption of a low-fat diet) and
stage of change for achieving these behav-
iors(25–27).Toassessbehavioralchanges,
we measured number of sessions attended
for the 12-week Lifestyle Balance program
because prior research has demonstrated
ap o s i t i v ed o s e –response relationship be-
tween attendance and diabetes prevention
(28).Finally,wealsoassessedweightchange
from baseline to program completion.
Statistical analyses
For our primary analyses, we examined
changes in self-reported responses from
baseline to study end, separately compar-
ing higher-risk and lower-risk recipients
with untested control participants. The
study was designed to have sufﬁcient
power for assessing 1) the difference be-
tween comparison arms from baseline to
study completion in self-reported stages
of change, and 2) differences in program
attendance.Weestimatedthatwith30in-
tervention participants in each arm and
30controlparticipants,wehad97%power
to detect a 90% increase in higher-risk in-
terventionpatientsversusa50%increasein
control participants regarding stage of
change at 0.05 two-sided signiﬁcance and
78%powertoshowa21%decreaseinmo-
tivation comparing lower-risk intervention
patients with control participants. For at-
tendance,weestimatedthatthestudysam-
ple size would provide 96% power to
detect a 20% difference in number of dia-
betespreventionsessionsattended(i.e.,dif-
ference of 1.7 visits assuming that control
participants attended 8.5 of 12 visits).
For stages ofchange,wedichotomized
the results into percentage of participants
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Genetic risk counseling for diabetes preventionwho improved or increased versus all
others. Changes from baseline in 10-point
scales for motivation and conﬁdence were
analyzed as continuous data using t tests
and dichotomized data (increase vs. no in-
crease) using x
2 tests. Program attendance
was analyzed as a continuous variable
(using t tests and Wilcoxon rank sum to
compare means and medians) and also di-
chotomized as proportion of participants
attending at least seven sessions (a thresh-
old consistent with the Centers for Disease
Control and Prevention’s attendance crite-
riafordiabetespreventionrecognitionpro-
grams) (29) as the goal for group-based
diabetes prevention programs. All analyses
were intention-to-treat.
In a planned secondary analysis, we
also compared the relative effect and
durability of the genetic counseling
intervention between higher- versus
lower-risk intervention recipients after
completion of the 12-week program.
RESULTS
Study participants
We contacted 687 potentially eligible
participants by telephone. After exclud-
ing ineligible 83 individuals, 177 of 604
participants (29.3%) consented to partic-
ipate. Study allocation arms were well
balanced (Table 1). All participants
reported high motivation (9.4 on a scale
of 0–10) to prevent diabetes, although
motivation and conﬁdence for making
speciﬁc changes involving weight loss,
diet, and increasing exercise were lower,
ranging from 6.8 to 8.4.
Changes in self-reported attitudes
Enrollment in the 12-week diabetes pre-
vention program led to small, generally
favorable changes in risk perception, mo-
tivation (with the exception of exercise),
and conﬁdence that were not statistically
different comparing higher- or lower-risk
result recipients with control participants
(Table 2). There was some evidence that
lower-risk resultrecipientshad lessintent
to exercise, with 37.5% of these partici-
pants increasing their stage of change for
exercise compared with 64.7% of control
participants (P = 0.03).
Differences in program attendance
and weight loss
Study participants attended a mean of
6.8 6 4.3 of 12 diabetes prevention group
sessions. The 12-week Lifestyle Change
program had a beneﬁcial overall effect,
with enrollees losing a mean of 8.5 6 10.1
pounds (P , 0.001) and 33 of 108 partic-
ipants (30.6%) losing $5% body weight.
However, despite clear room for improve-
ment in program attendance and goal
weight achievement, receipt of personal ge-
netic risk information and counseling had
nostatisticallysigniﬁcanteffectonmeasured
b e h a v i o r sc o m p a r e dw i t hu n t e s t e dc o n t r o l
participants (Table 3 and Fig. 1). Recipients
of higher-risk results attended 0.4 more ses-
sions (95% CI 21.6 to 2.5; P =0 . 6 7 )
and lost more weight (BMI difference 20.2
kg/m
2 [20.5 to 0.9]; P = 0.52) compared
with control participants. Lower-risk recipi-
entsattended0.3fewersessions(21.9to2.4;
P = 0.82) and also lost more weight (BMI
difference 20.3 kg/m
2 [20.5 to 1.1]; P =
0.48) compared with control participants.
Table 1dBaseline characteristics of the 116 participants by intervention allocation
Control
subjects
Higher
genetic
risk
Lower
genetic
risk
n =3 8 n =4 4 Pn =3 4 P
Age (years), mean 6 SD 59.6 6 10.8 56.2 6 8.9 0.12 61.0 6 12.0 0.61
Male sex, n (%) 25 (65.8) 25 (56.8) 0.41 19 (55.9) 0.39
Race, n (%)
B l a c k 1( 2 . 6 ) 3( 6 . 8 ) 0 . 6 3 0 1 . 0
W h i t e 3 2( 8 4 . 2 ) 3 3( 7 5 . 0 ) 3 0( 8 8 . 2 )
Other 5 (13.2) 8 (18.2) 4 (11.8)
BMI (kg/m
2), mean 6 SD 34.7 6 3.6 34.8 6 5.5 0.96 36.1 6 6.2 0.27
Annual household income, n (%)
,$50,000 13 (36.1) 12 (27.9) 0.55 12 (37.5) 0.39
$50,000–99,000 9 (25.0) 9 (20.9) 12 (37.5)
.$100,000 14 (38.9) 22 (51.2) 8 (25.0)
Education, n (%)
#12th grade or General
Educational Development test 4 (10.5) 8 (18.2) 0.5 12 (35.3) 0.05
1–3 years of college 13 (34.2) 11 (25.0) 9 (26.5)
$ 4y e a r so fc o l l e g e 2 1( 5 5 . 3 ) 2 5( 5 6 . 8 ) 1 3( 3 8 . 2 )
Family history of diabetes, n (%) 19 (50.0) 25 (56.8) 0.54 21 (61.8) 0.32
Current health, n (%)
Poor 0 0 0.73 1 (2.9) 0.72
Fairly poor 4 (10.5) 3 (6.8) 4 (11.8)
Average 14 (36.8) 16 (36.4) 9 (26.5)
Good 14 (36.8) 14 (31.8) 16 (47.1)
Very good 6 (15.8) 11 (25.0) 4 (11.8)
Diabetes risk perception
(% reporting “moderate/high” risk) 73.5 65.6* 0.47 68.8 0.69
Motivation (10-point scale) for
Weight loss 8.0 8.3 0.44 8.1 0.80
Dietary change 7.8 8.3 0.16 8.1 0.38
Exercise increase 8.2 8.4 0.54 8.0 0.70
Diabetes prevention 9.4 9.5 0.84 9.5 0.85
Conﬁdence (10-point scale) for
Weight loss 7.0 7.6 0.19 6.8 0.69
Dietary change 7.3 8.0 0.15 7.0 0.58
Exercise increase 7.8 7.9 0.74 7.0 0.13
Diabetes prevention 8.2 8.1 0.86 7.7 0.33
Stage of change
(% in action/maintenance)
Weight loss 12 (35.2) 15 (35.7) 0.97 9 (28.1) 0.53
Diet 5 (15.2) 10 (23.8)* 0.35 4 (12.5)* 0.76
Exercise 8 (23.5) 13 (31.0) 0.47 5 (15.6) 0.41
P values compare higher-risk recipients vs. control participants and lower-risk recipients vs. control par-
ticipants. Race, income, education, and family history of diabetes are self-reported. Motivation and conﬁ-
dence questions are based on 10-point Likertscales ranging from 0 (not at all) to 10(highest motivation/very
conﬁdent). Prochaska stages of change progress from precontemplative to contemplative, preparation, ac-
tion, and maintenance (25–27). *One missing response.
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Grant and AssociatesSecondary analysis of higher- versus
lower-risk intervention arms
After completing the 12-week prevention
program, 74 intervention participants
(96% ) recalled their diabetes genetic
risk status (e.g., “higher” or “lower”), al-
though only 2 (3%) could accurately re-
call their numeric genetic risk score. In
an exploratory analysis, we found that
higher-risk result recipients more often
reported that the initial genetic counseling
intervention had made them “much more/
somewhat more” motivated to participate
inthe12-weekprogram(78.6%vs.43.8%
for lower-risk participants, P =0 . 0 0 3 )
and to make lifestyle changes to prevent
diabetes(85.7%vs.56.3%forlower-risk
participants, P = 0.008). A signiﬁcant
proportion of lower-risk result recipi-
ents reported that they had not thought
about their genetic risk results in the
prior 3 months (43.8% vs. 16.7% of
higher result recipients, P =0 . 0 2 ) .D e -
spite these self-reported differences,
program attendance and weight loss
were not statistically different when the
two intervention arms were compared
(P . 0.05).
CONCLUSIONSdAmong overweight
primary care patients at increased pheno-
typic risk for type 2 diabetes, receiving a
higher genetic risk result and counseling
did not signiﬁcantly improve motivation
toadoptdiabetespreventionbehaviorsor
signiﬁcantly increase program atten-
dance or weight loss compared with un-
tested control patients. Conversely,
receiving a lower genetic risk result did
not appear to signiﬁcantly detract from
motivation or attendance.
The GC/LC Study is one of the ﬁrst
rigorous, controlled trials to directly ad-
dress the effect of diabetes genetic risk
information on patient behavior. Our
study has several important strengths.
We designed our genetic counseling in-
tervention to be intensive yet relatively
brieftomaximize thetranslatabilitytothe
real-world clinical setting. Delivered by
an experienced genetic counselor, the
counseling intervention was designed to
educate recipients about the relative con-
tributions of both genetic and behavioral
risk and to emphasize that changing their
behavior could reduce their overall di-
abetes risk. This approach received pos-
itive preliminary feedback by study
participants for its effect on perceived
control and general satisfaction with the
genetic counseling process (24). Cru-
cially, all study participants were then en-
r o l l e di na ne v i d e n c e - b a s e da n dv a l i d a t e d
diabetes prevention program designed to
provide them with the tools and skills
necessary to achieve the required behav-
ior changes for diabetes prevention. We
believe that using the genetic test disclo-
sure as a “teachable moment” to engage
patients in risk-reducing behavior change
represents a powerful model for how ge-
netictestingforcommonchronicdiseases
can be implemented into primary care
practice. By coupling information (ge-
netic test results and counseling) to a
mechanism for participants to act on the
information (diabetes prevention pro-
gram), the GC/LC Study created an ideal
context for genetic testing to succeed as a
motivator.
Our study was also designed to di-
rectly address the potential for false
reassurance from receiving results
showing a lower genetic risk, particularly
among patients with increased risk based
on family history or validated phenotypic
m e a s u r e s .W ed i dn o tu n c o v e ras t r o n g
negative inﬂuence of receiving a “lower”
risk result, with the possible exception of
one exercise measure. From our exit sur-
veys, it appears that many lower-risk re-
cipients underemphasized their genetic
test results. We suspect that most of the
genetically tested patients with average
resultswouldhavehadasimilarresponse,
indicating that diabetes genetic risk
Table 2dChanges from baseline in self-reported measures of risk perception, motivation,
conﬁdence, and stage of change for diabetes prevention behaviors, comparing recipients
of higher and lower genetic risk results with untested control subjects
Control Higher Lower
n =3 4 n =4 2 Pn =3 2 P
Increased diabetes risk perception 4 (11.8) 9 (22.0)* 0.25 1 (3.1) 0.18
Increased motivation
Weight loss 17 (50.0) 12 (28.6) 0.056 13 (40.6) 0.44
Dietary change 15 (44.1) 16 (38.1) 0.60 12 (37.5) 0.58
Exercise increase 11 (32.4) 10 (23.8) 0.41 8 (25.0) 0.51
Diabetes prevention 3 (8.8) 7 (16.7) 0.31 5 (15.6) 0.40
Increased conﬁdence
Weight loss 18 (52.9) 15 (35.7) 0.13 18 (52.9) 0.21
Dietary change 16 (47.1) 20 (47.6) 0.96 11 (35.5)* 0.34
Exercise increase 14 (41.2) 17 (40.5) 0.95 11 (34.4) 0.57
Diabetes prevention 11 (32.4) 17 (40.5) 0.47 13 (41.9)* 0.42
Increased in stage of change
Weight loss 20 (58.8) 22 (53.7) 0.65 19 (59.4) 0.96
Diet 17 (51.5) 21 (50.0) 0.90 12 (40.0) 0.36
Exercise 22 (64.7) 19 (45.2) 0.09 12 (37.5) 0.03
Data are shown as n (%). P values compare higher-risk recipients vs. control participants and lower-risk
recipients vs. control participants. Number (%) with increased motivation and conﬁdence based on im-
provement from baseline in response to 10-point Likert scale ranging from 0 (not at all) to 10 (very conﬁdent/
highest motivation). Prochaska stages of change progress from precontemplative to contemplative, preparation,
action, and maintenance (25–27). *One missing response.
Table 3dDifferences in program attendance and weight loss, comparing recipients of
higher and lower genetic risk results with untested control subjects
Control Higher Lower
n =3 4 n =4 2 Pn =3 2 P
Classes attended of 12 scheduled
Mean 6 SD 6.6 6 4.7 7.0 6 4.0 0.67 6.8 6 4.2 0.82
Median (interquartile range) 9 (1–11) 8 (3–11) 0.84 8 (3.5–10) 0.97
Attended $7 classes, n (%) 20 (58.8) 26 (61.9) 0.78 20 (62.5) 0.76
Weigh loss (pounds), mean 6 SD 7.52 6 9.59 8.74 6 9.60 0.58 9.18 6 11.6 0.53
BMI reduction (kg/m
2), mean 6 SD 1.02 6 1.45 1.23 6 1.47 0.52 1.30 6 1.80 0.48
Lost 7% body weight, n (%) 6 (17.7) 10 (23.8) 0.51 6 (18.8) 0.91
P values compare higher-risk recipients vs. control subjects and lower-risk recipients vs. control subjects.
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Genetic risk counseling for diabetes preventiontesting and counseling, even if it ulti-
mately provides greater predictive power,
will likely have little beneﬁt but will do
little harm for most tested patients who
do not have higher results.
Despite these study strengths, several
limitations must be considered. Perhaps
foremost of these is the limited predictive
value of current diabetes genetic risk test-
ing, which required us to focus on the
highest-risk patients to maximize the re-
sulting contrast between tested and un-
testedparticipants.Eveninthisgroup,with
an estimated 3-year risk for diabetes of
11%,therecalculatedriskbasedonrelative
genetic risk results resulted in only modest
changes. Thus, we do not know whether
greater genetic predictive ability in the
future will have a bigger impact on chang-
ing behavior. However, given that 96% of
ourinterventionpatientsrememberedtheir
qualitative genetic risk (i.e., “higher” or
“lower”) but not their quantitative risk
score (provided as a hand-out during the
counseling session), we suspect that mar-
ginal improvements in risk prediction will
not lead to substantially greater impact on
patient behavior.
Another limitation of current genetic
knowledge is that results do not alter the
actual behavioral intervention; thus, al-
though the risk information is personal-
ized, the intervention itself is not. The
Diabetes Prevention Program recently
showed that an intensive lifestyle inter-
vention beneﬁts participants regardless of
overallgeneticrisk(30),butfutureresearch
focused on unique gene-environment in-
teractions may help to further tailor inter-
ventions (e.g., some patients may beneﬁt
preferentially from caloric restriction or
certain dietary plans, others from aero-
bic exercise or resistance training) (31)
and therefore lead to truly personalized
behavioral treatments. Finally, although
we cannot exclude small differences
in self-reported measures that did not
reach statistical signiﬁcance, we have
good conﬁdence that any difference in
self-reported measures did not translate
into signiﬁcant changes in attendance
behavior.
Our results must be considered
within the context of the study design.
Werandomizedintwostagestoprovidea
clinically relevant test of genetic testing
versus no testing on preventive behavior,
while also efﬁciently focusing on the
genetic risk extremes among tested par-
ticipants. For the second-stage allocation
of intervention participants, we relied on
the concept of Mendelian randomization
(e.g., the random allocation of parental
alleles during gametogenesis) to identify
top and bottom quartiles of genetic risk
scoredistribution(32).Astrategyofusing
the lowest quartile of score as “normal”
w o u l dh a v ei n c r e a s e dt h ee f f e c ts i z ei n
the highest quartile and would have elim-
inated the problem of presenting “lower”
genetic risk results to otherwise pheno-
typically high-risk individuals. However,
it seemed unethical to portray low-score
outliers as normal given the population
distribution in which the vast majority
of individuals fall within a relatively nar-
row middle range. In addition, creating
more extreme cut points, such as the top
decile of risk, would have resulted in
higher relative risk differences at the ex-
pense of identifying an increasingly
smaller number of participants, which
would have diminished the clinical rele-
vance of our results.
Focusing as wedidonphenotypically
high-risk participants might have limited
the effect ofthe genetic risk results because
these participants might already have been
maximally motivated. The paradox of this
limitationisthat lessmotivated individuals
arealsolesslikelytobeinterestedingenetic
testing. Given the modest success rate
among control participants in our study
and among other community-based pro-
grams described in the literature (8–11),
new tools to achieve enduring behavior
change are clearly needed. One challenge
for the future is to identify the subset of
patients for whom genetic test results rep-
resent the tipping point from inaction
to action.
Our ﬁn d i n g sb u i l do na ne m e r g i n g
literature in translational genomics and
health outcomes (33–35) and have im-
plications for current direct-to-consumer
home genetic testing (36). Such tests may
beneﬁtself-selectedindividualsbutmay
also have negative consequences in
patient-borne costs and the potential for
triggering expensive diagnostic cascades
(37). Without further evidence of efﬁcacy
from controlled clinical trials, such testing
cannot yet be recommended in routine
clinicalcarefordiabetesprevention.Other
importantapplicationsofpersonalizedge-
netictestingdeservefurtherstudy,includ-
ing clinically applied pharmacogenomic
proﬁling(38)andevaluationofphenotyp-
ically lower-risk younger patients who
have yet to manifest diabetes-related phe-
notypic traits.
In summary, a diabetes genetic risk
assessment and counseling intervention
for overweight individuals based on 36
single nucleotide polymorphisms neither
improved nor substantially detracted
from an evidence-based behavioral inter-
vention to prevent diabetes.
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